Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy
Status:
Completed
Trial end date:
2019-03-01
Target enrollment:
Participant gender:
Summary
The study evaluates the safety and effect of intralymphatic allergen specific immunotherapy
in increasing doses. Patients that have already undergone subcutaneous immunotherapy will be
treated with three intralymphatic injections in increasing doses; 1000 SQ-U, 3000 SQ-U and 10
000 SQ-U, or placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Karolinska Institutet
Collaborators:
Karolinska University Hospital Skane University Hospital Sodra Alvsborgs Hospital